Comerica Bank Lowers Holdings in Amedisys, Inc. (NASDAQ:AMED)

Comerica Bank decreased its position in Amedisys, Inc. (NASDAQ:AMEDGet Rating) by 2.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,074 shares of the health services provider’s stock after selling 307 shares during the quarter. Comerica Bank’s holdings in Amedisys were worth $1,475,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. raised its holdings in Amedisys by 862.5% in the second quarter. First Horizon Advisors Inc. now owns 385 shares of the health services provider’s stock valued at $40,000 after acquiring an additional 345 shares in the last quarter. Neo Ivy Capital Management acquired a new stake in Amedisys in the second quarter valued at approximately $44,000. Covestor Ltd raised its holdings in Amedisys by 88.9% in the first quarter. Covestor Ltd now owns 323 shares of the health services provider’s stock valued at $56,000 after acquiring an additional 152 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in Amedisys in the first quarter valued at approximately $68,000. Finally, Field & Main Bank raised its holdings in Amedisys by 17.7% in the second quarter. Field & Main Bank now owns 665 shares of the health services provider’s stock valued at $70,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 96.17% of the company’s stock.

Amedisys Stock Performance

NASDAQ:AMED opened at $95.47 on Monday. The firm’s fifty day moving average price is $86.16 and its 200 day moving average price is $102.44. Amedisys, Inc. has a 1-year low of $79.30 and a 1-year high of $179.91. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of 25.73, a price-to-earnings-growth ratio of 2.30 and a beta of 0.96.

Amedisys (NASDAQ:AMEDGet Rating) last posted its quarterly earnings data on Wednesday, October 26th. The health services provider reported $1.15 earnings per share for the quarter, missing analysts’ consensus estimates of $1.24 by ($0.09). Amedisys had a net margin of 5.45% and a return on equity of 16.00%. The firm had revenue of $557.99 million during the quarter, compared to analysts’ expectations of $579.30 million. During the same quarter last year, the business earned $1.53 earnings per share. The business’s quarterly revenue was up .8% on a year-over-year basis. On average, sell-side analysts expect that Amedisys, Inc. will post 4.83 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on AMED shares. SVB Leerink reduced their target price on shares of Amedisys from $96.00 to $85.00 and set a “market perform” rating on the stock in a report on Thursday, January 5th. StockNews.com raised shares of Amedisys from a “hold” rating to a “buy” rating in a report on Wednesday, January 18th. UBS Group cut their price objective on shares of Amedisys to $88.00 in a report on Friday, November 4th. Benchmark cut their price objective on shares of Amedisys from $165.00 to $135.00 and set a “buy” rating on the stock in a report on Monday, October 3rd. Finally, Raymond James cut shares of Amedisys from an “outperform” rating to a “market perform” rating in a report on Thursday, October 27th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $134.19.

Amedisys Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Stories

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.